Revenue Growth and Lower Cost of Revenue
Q2 FY2026 revenue increased 2.1% YoY to $145M, while cost of revenue dropped 21.8% YoY to $93M, helping generate a gross profit of $52M compared to a gross loss in the prior-year period.
Moderna, Inc. is expected to release its Q3 2026 10-Q filing in the upcoming earnings season. Last quarter: Moderna (MRNA) reported Q2 FY2026 revenue of $145M (+2.1% YoY) and narrowed its net loss to -$782M, supported by a 21.8% decline in cost of revenue and lower R&D expenses.
Drawn from management commentary in the Q2 2026 10-Q:
Q2 FY2026 revenue increased 2.1% YoY to $145M, while cost of revenue dropped 21.8% YoY to $93M, helping generate a gross profit of $52M compared to a gross loss in the prior-year period.
Research and development spending decreased 7.0% YoY to $651M, contributing to a 10.1% YoY improvement in operating loss to -$815M.
Total liabilities expanded 60.9% YoY to $4.20B, driven by $591M in long-term debt additions, while total assets declined 8.7% YoY to $10.96B.
Revenue
$145M
+2.11% YoY
EPS (Diluted)
-$1.97
+7.51% YoY
Operating Income
-$815M
+10.14% YoY
Add MRNA to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.